RESUMO
El tratamiento hipolipemiante es uno de los pilares de la prevención cardiovascular; en la prevención secundaria de pacientes con cardiopatía isquémica, es una de las estrategias de mayor eficacia, pero el tratamiento hipolipemiante actual, junto con cambios en el estilo de vida, en una importante proporción de pacientes no consigue alcanzar los objetivos recomendados por las guías de práctica clínica. Los inhibidores PCSK9 han mostrado eficacia y seguridad en el tratamiento de la dislipemia y se han incorporado recientemente en España para empleo clínico con el objetivo de reducir el riesgo cardiovascular debido a su efecto en la reducción del colesterol unido a lipoproteínas de baja densidad (AU)
Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups (AU)
Assuntos
Humanos , Hipolipemiantes/uso terapêutico , Hiperlipidemias/tratamento farmacológico , Doença das Coronárias/complicações , Anticorpos Monoclonais/uso terapêutico , Avaliação das Necessidades , Hiperlipidemias/epidemiologia , Padrões de Prática Médica , SubtilisinaRESUMO
Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups.
Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hiperlipidemias/tratamento farmacológico , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Inibidores de PCSK9 , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Cardiologia , LDL-Colesterol/sangue , Humanos , Hiperlipidemias/sangue , Hiperlipoproteinemia Tipo II/sangue , Planejamento de Assistência ao Paciente , Prevenção Primária , Prevenção Secundária , Sociedades Médicas , EspanhaRESUMO
The Spanish Society of Cardiology (SEC) has produced an Ethical Framework Document. This document is divided into two distinct parts that deal, respectively, with the responsibilities of the SEC as an organization and the responsibilities of its professional members. The SEC makes recommendations on how its members should carry out their daily clinical practice, provides a professional perspective on public commitments as a scientific association, and aims to ensure that any views, recommendations, and advice expressed provide the basis for an informed debate on ethical problems in our field of work.
Assuntos
Cardiologia/ética , Ética Institucional , Sociedades Médicas/ética , EspanhaRESUMO
La Sociedad Española de Cardiología (SEC) ha elaborado su «marco ético». Este documento se estructura en 2 partes diferenciadas que tratan sobre la responsabilidad de la SEC como organización y de los profesionales en tanto que socios. La SEC propone a sus miembros unas pautas de actuación en su práctica diaria, establece un horizonte de compromiso cívico como asociación científica, y desea que las reflexiones, las recomendaciones y los consejos reflejados sirvan para debatir responsablemente sobre los problemas éticos de nuestro quehacer
The Spanish Society of Cardiology (SEC) has produced an Ethical Framework Document. This document is divided into two distinct parts that deal, respectively, with the responsibilities of the SEC as an organization and the responsibilities of its professional members. The SEC makes recommendations on how its members should carry out their daily clinical practice, provides a professional perspective on public commitments as a scientific association, and aims to ensure that any views, recommendations, and advice expressed provide the basis for an informed debate on ethical problems in our field of work
